TABLE 1
FROM:
Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection
B J Byrne, M Horwitz, G D Long, C Gasparetto, K M Sullivan, J Chute, N J Chao and D A Rizzieri
BACK TO ARTICLETable 1. Patient characteristics and outcomes
| Age at first transplant | Disease | First preparatory regimen | Donor HLA match | Engrafted | Time to second transplant (months) | Second preparatory regimen | Donor HLA match | Engrafted | Survival from second transplant | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 | Thalassemia | FCC | Sib 6/6 | No | 25.8 | Same | Sib, 6/6 | Yes, RFLP 23% | Alive, 5 years | N/A |
| 42 | Nodal marginal zone lymphoma | FCC | Father 4/6 | No | 3.2 | Same | Sib, 3/6 | Yes, RFLP 3% | Died 1,1 month | TRM: diffuse alveolar hemorrhage |
| 42 | Renal cell | FCC | Son 3/6 | No | 2.1 | Same | Same | No | Died 3, 2 months | PD |
| 49 | AML | FCC | Sib 4/6 | No | 2.3 | Same | Daughter, 4/6 | Yes, RFLP 96% | Alive, 10 months | N/A |
| 47 | Mantle cell/MDS | FCC | Son 4/6 | No | 2.3 | Same | Son, 3/6 | Yes, RFLP 97% | Died, 7 months | PD |
| 50 | MDS/AML | FCC | Daughter 3/6 | No | 2.3 | Same | Different daughter, 3/6 | Yes, RFLP 39% | Alive, 7 months | N/A |
| 68 | Myelofibrosis/AML | One day | Sib 6/6 | Yes, RFLP 63% | 14 | FCC | Same | Yes, RFLP 98% | Alive, 2.5 years | N/A |
| 59 | CML | FCC | Sib 4/6 | Yes, RFLP 61% | 4.2 | Same | Sib, 4/6 | Yes, RFLP 9% | Died, 9.5 months | PD |
| 55 | Renal cell | FCC | Sib 3/6 | Yes, RFLP 30% | 3 | Same | Same | Yes, RFLP 94% | Died, 1 month | PD |
| 33 | MDS/AML | FCC | Father 4/6 | Yes, RFLP 5% | 1.7 | Same | Same | No, engrafted with third trans. | Died, 7.6 months | TRM: infections |
| 34 | AML | One day | Sib 3/6 | Yes, RFLP 44% | 2.5 | FCC | Father, 3/6 | Yes, RFLP 98% | Alive, 3 years | N/A |
Abbreviations: FCC=fludarabine 30 mg/m2 on days -5 to -1 (150 mg/m2 total), cyclophosphamide 500 mg/m2 on days -5 to -2 (2000 mg/m2 total) and alemtuzumab 20 mg on days -4 to 0; N/A=not applicable; one day=fludarabine 30 mg/m2, cyclophosphamide 2000 mg/m2, alemtuzumab 20 mg and TBI 200 cGy all delivered on day -1; PD=progressive disease; Sib=sibling; TRM=treatment-related mortality.
